Article

Modeling the Cost-Effectiveness of the Next-Generation COVID-19 mRNA-1283 vaccine in the United States

2025-12-02

Abstract excerpt

<h4>Aims</h4> COVID-19 disease burden in United States (US) adults ≥65 years and persons with underlying medical conditions remains high. This modeling study estimates the cost-effectiveness of the next-generation COVID-19 mRNA-1283 vaccine in those ages 12-64 at high-risk of severe COVID-19 outcomes and all adults ≥65 years. <h4>Methods</h4> mRNA-1283 was compared to no annual vaccination and originally license...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 93357ea9-1aa9-5797-b25c-058d1e0c47fe
DOI: 10.64898/2025.12.01.25341380

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Modeling the Cost-Effectiveness of the Next-Generation COVID-19 mRNA-1283 vaccine in the United StatesDOI 10.64898/2025.12.01.25341380Read

Modeling the Anticipated Public Health Benefits of the Next-Generation COVID-19 mRNA-1283 vaccine: An Interim U.S. Population-Level Impact AssessmentSemantic proximity Read

The Potential Clinical and Economic Impact of the Next-Generation COVID-19 mRNA-1283 Vaccine in CanadaSemantic proximity Read

Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine (mRNA-1273.815) in preventing COVID-19-related hospitalizations and medical encounters among adults in the United States: An interim analysisSemantic proximity Read

Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in FranceSemantic proximity Read

Effectiveness of the 2023–2024 Omicron XBB.1.5-containing mRNA COVID-19 Vaccine (mRNA-1273.815) in Preventing COVID-19–related Hospitalizations and Medical Encounters Among Adults in the United StatesSemantic proximity Read

Real-World Effectiveness of the mRNA-1273 Vaccine Against COVID-19: Interim Results from a Prospective Observational Cohort StudySemantic proximity Read

The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Fall 2023 vaccines in the United StatesSemantic proximity Read

Comparative effectiveness of mRNA-1273 versus protein-based NVX-CoV2705 vaccination on COVID-19-related outcomes among US insured adults during 2024–2025: a retrospective matched cohort studySemantic proximity Read

Clinical and Economic Impact of Differential COVID-19 Vaccine Effectiveness in the United StatesSemantic proximity Read

Clinical and Economic impact of updated Fall 2023 COVID-19 vaccines in the Immunocompromised Population in CanadaSemantic proximity Read

Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE FrameworkSemantic proximity Read

Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United StatesSemantic proximity Read